The (Fab)ulous Destiny of Idarucizumab: Highlighting Its Interference with Urine Protein Immunofixation

Nicolas Gendron^{1,2} Héloïse Flament^{3,4} Elena Litvinova^{3,4} Sofia Ortuno⁵ Nadine Ajzenberg^{1,2} Dorothée Faille^{1,2}

¹Laboratoire d'Hématologie, Hôpital Bichat-Claude Bernard, AP-HP, Paris, France

²Université de Paris, INSERM, U1148, Paris, France

³Laboratoire d'Immunologie-Hématologie, Hôpital Bichat-Claude Bernard, AP-HP, Paris, France

⁴Université de Paris, INSERM, U1149, Paris, France

⁵Service de Néphrologie, Hôpital Bichat-Claude Bernard, AP-HP, Paris, France

Address for correspondence Dorothée Faille, PharmD, PhD, Department of Hematology, Bichat-Claude Bernard Hospital, 46 Rue Henri Huchard, 75877 Paris, France (e-mail: dorothee.faille@aphp.fr).

TH Open 2019;3:e306–e308.

Abstract

Keywords

- ▶ idarucizumab
- ▶ dabigatran
- ▶ reversal
- ▶ immunofixation
- ▶ paraprotein

Idarucizumab is a humanized antigen binding fragment (Fab) of a recombinant anti-dabigatran monoclonal antibody (IgG1-kappa) that allows rapid and sustained reversal of dabigatran-induced anticoagulation in case of bleeding or urgent surgery. Herein, we report a very unusual case of dabigatran reversal by idarucizumab in a 79-year-old woman with acute kidney failure admitted to a hospital in a context of hemoptysis. Three repeated injections were necessary because of massive dabigatran overdose and high rebounds of dabigatran plasma concentration. Idarucizumab was found on urine immunofixation up to 6 days after the last injection where it reacted with anti-kappa light chain antibody, but not with anti-gamma heavy chain antibody. Physicians should be aware of the increased half-life of idarucizumab in this context of acute kidney impairment and of its interference with urine immunofixation because it could lead to false-positive results and misdiagnosis of a paraprotein.

Introduction

Idarucizumab is a humanized monoclonal antigen binding fragment (Fab G1-kappa) that specifically neutralizes anti-coagulant effect of dabigatran^{1,2} and can be used in emergency situations.³

A 79-year-old woman was admitted to an emergency department for hemoptysis and progressive asthenia. She was taking dabigatran etexilate (150 mg twice daily) for non-valvular atrial fibrillation. On admission, her full blood count revealed a hemoglobin concentration of 80 g/L, mild leucocytosis, and a normal platelet count. Laboratory investigations showed elevated urea and creatinine levels at 40.9 mmol/L and 1,031 µmol/L respectively, associated with massive dabigatran overdose (plasma concentration 2,881 ng/mL, Hemoclot

Thrombin Inhibitor, Hyphen BioMed). She received two first intravenous infusions of 2.5 g idarucizumab within 15 minutes of each other few hours after admission. Two additional injections (2 × 2.5 g each) were performed at days 2 and 5 due to high rebound of plasma dabigatran after each reversion (▶ **Fig. 1A**) and because a kidney biopsy was then considered, although no bleeding event was observed during hospitalization. Serum and urine immunofixation (IF) were performed to exclude multiple myeloma in this context of isolated, nonregenerative normocytic anemia and renal failure. At day 5, serum IF was normal whereas urine IF showed isolated monoclonal kappa light chains (KLCs, ▶ **Fig. 1B**, black arrow). Surprisingly, no free KLC was detected (▶ **Fig. 1B**) and serum free light chain ratio was normal. Urine IF was repeated daily until progressive disappearance of monoclonal KLC

received
April 15, 2019
accepted after revision
August 5, 2019

DOI <https://doi.org/10.1055/s-0039-1697642>.
ISSN 2512-9465.

© 2019 Georg Thieme Verlag KG
Stuttgart · New York

License terms

Fig. 1 Plasma dabigatran concentration (A) and urine immunofixation (B–E) after three injections of idarucizumab. At day 5 (B), monoclonal kappa light chains (KLC, *black arrow*) with no corresponding gamma, alpha, delta, or epsilon heavy chains and no corresponding free KLC. Progressive disappearance of KLC at days 9 (C) and 11 (D). Complete disappearance at day 12 (E).

(► **Fig. 1C–E**). Bone marrow aspiration excluded hematologic malignancies.

The patient was diagnosed with end-stage renal disease and referred to a dialysis center. Anticoagulation was resumed with warfarin. Her last creatinine clearance estimation performed 14 months ago was of 38.5 mL/min (Cockcroft-Gault) and confirmed chronic impaired kidney function. This underlines the importance of regular assessment of renal function in patients receiving dabigatran and of a dose reduction according to the label recommendation in the case of renal impairment.

Idarucizumab, dabigatran, and idarucizumab–dabigatran complexes are mainly excreted in urine.⁴ Thus, idarucizumab

can be detected on urine IF where it reacts with anti-KLC antibody, but not with anti-gamma heavy chain antibody because it lacks the two heavy chains composing Fc portion. Idarucizumab clearance is reduced in the case of renal impairment, leading to increased half-life and sustained urine excretion. However, one single injection of 5 g idarucizumab was insufficient to neutralize dabigatran. This case also illustrates our previous findings that an initial dabigatran plasma level ≥ 200 ng/mL before idarucizumab injection could predict dabigatran plasma rebound.⁵

In this rare context of acute kidney impairment and repeated injections of idarucizumab, idarucizumab should not be misdiagnosed with paraprotein on urine IF.

Conflict of Interest

N.G. and D.F. declare financial support by Boehringer Ingelheim. This sponsor had no role in study design; collection, analysis, and interpretation of the data; writing of the report; and decision to submit the report for publication.

Acknowledgments

The authors thank all the technicians from the Department of Biological Hematology and Immunology for technical assistance.

References

- 1 Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. *Blood* 2013;121(18):3554–3562
- 2 Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. *Lancet* 2015;386(9994):680–690
- 3 Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal: full cohort analysis. *N Engl J Med* 2017;377(05):431–441
- 4 Glund S, Gan G, Moschetti V, et al. The renal elimination pathways of the dabigatran reversal agent idarucizumab and its impact on dabigatran elimination. *Clin Appl Thromb Hemost* 2018;24(05):724–733
- 5 Gendron N, Gay J, Lemoine M, Gaussem P, Lillo-Le-Louet A, Smadja DM. Usefulness of initial plasma dabigatran concentration to predict rebound after reversal. *Haematologica* 2018;103(05):e226–e229